



## Stedman's Medical Dictionary

---

**gonad** (go'nad)

An organ that produces sex cells; a testis or an ovary. [Mod. L. fr. G. *gone*, seed]

**female g.** ovary

**indifferent g.** the primordial organ in an embryo before its differentiation into testis or ovary. See indifferent genitalia.

**male g.** testis

**streak g.** gonadal streak

*Copyright© 1995 Williams & Wilkins. All rights reserved.*

Copyright © 2001 by Medical Economics Company, Inc. at Montvale, NJ 07645. All rights reserved.  
Monographs from the 2001 Physicians Desk Reference  
Click here to read our Warranty and Disclaimer.

=> d his

(FILE 'HOME' ENTERED AT 16:44:08 ON 09 APR 2001)

FILE 'EUROPATFULL, PCTFULL, USPATFULL' ENTERED AT 16:44:55 ON 09 APR 2001

L1	6709 S TESTOSTERONE
L2	3769 S SILDENAFIL OR YOHIMBINE OR PENTOXIFYLINE OR APOMORPHINE OR
AL	
L3	351 S L1(L)L2
L4	235 S L3(L) (SEX? OR DYSFUNCTION OR ERECT? OR IMPOTEN?)
L5	235 DUP REM L4 (0 DUPLICATES REMOVED)
L6	26 S L4/CLM

=> d ibib 9-26

L6 ANSWER 9 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent  
ACCESSION NUMBER: 1998057642 PCTFULL  
TITLE (ENGLISH): ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS  
TITLE (FRENCH): ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1A  
INVENTOR(S): PATANE, Michael, A.; BOCK, Mark, G.  
PATENT ASSIGNEE(S): MERCK & CO., INC.  
LANGUAGE OF PUBL.: English  
LANGUAGE OF FILING: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9857642	A1	19981223
DESIGNATED STATES:	AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GW HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-US12678		19980617
PRIORITY (ORIGINAL):	US 1997-60/050126		19970618
	GB 1998-9800234.8		19980106

L6 ANSWER 10 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent  
ACCESSION NUMBER: 1998057639 PCTFULL  
TITLE (ENGLISH): ALPHA 1aADRENERGIC RECEPTOR ANTAGONISTS  
TITLE (FRENCH): ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a  
INVENTOR(S): PATANE, Michael, A.; BOCK, Mark, G.  
PATENT ASSIGNEE(S): MERCK & CO., INC.  
LANGUAGE OF PUBL.: English  
LANGUAGE OF FILING: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9857639	A1	19981223
DESIGNATED STATES:	AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GW HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-US12659		19980617
PRIORITY (ORIGINAL):	US 1997-60/050137		19970618
	GB 1998-9800456.7		19980109

L6 ANSWER 11 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent  
ACCESSION NUMBER: 1998057638 PCTFULL  
TITLE (ENGLISH): ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS  
TITLE (FRENCH): ANTAGONISTES DES ADRENORECEPTEURS ALPHA 1a  
INVENTOR(S): PATANE, Michael, A.; BOCK, Mark, G.; NEWTON, Randall,  
C.  
PATENT ASSIGNEE(S): MERCK & CO., INC.  
LANGUAGE OF PUBL.: English  
LANGUAGE OF FILING: English  
DOCUMENT TYPE: Patent

## PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9857638	A1	19981223
DESIGNATED STATES:	AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GW HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-US12567		19980617
PRIORITY (ORIGINAL):	US 1997-60/050959		19970618
	GB 1998-9800217.3		19980107

L6 ANSWER 12 OF 26  
ACCESSION NUMBER: PCTFULL COPYRIGHT 2001 MicroPatent  
1998057632 PCTFULL  
TITLE (ENGLISH): ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS  
TITLE (FRENCH): ANTAGONISTES DES ADRENORECEPTEURS ALPHA 1a  
INVENTOR(S): PATANE, Michael, A.; BOCK, Mark, G.; NAGARATHNAM,  
Dhanapalan; LAGU, Bharat; WONG, Wai, C.  
PATENT ASSIGNEE(S): MERCK & CO., INC.; SYNAPTIC PHARMACEUTICAL  
CORPORATION  
LANGUAGE OF PUBL.: English  
LANGUAGE OF FILING: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9857632	A1	19981223
DESIGNATED STATES:	AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GW HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-US12573		19980617
PRIORITY (ORIGINAL):	US 1997-60/050136		19970618
	GB 1998-9800219.9		19980107

L6 ANSWER 13 OF 26  
ACCESSION NUMBER: PCTFULL COPYRIGHT 2001 MicroPatent  
1998056914 PCTFULL  
TITLE (ENGLISH): MAMMALIAN MELANOCORTIN RECEPTORS AND USES  
TITLE (FRENCH): RECEPTEURS DE MELANOCORTINE MAMMALIENS ET LEURS  
UTILISATIONS  
INVENTOR(S): CONE, Roger, D.; CHEN, Wenbiao; LOW, Malcolm, J.  
PATENT ASSIGNEE(S): OREGON HEALTH SCIENCES UNIVERSITY  
LANGUAGE OF PUBL.: English  
LANGUAGE OF FILING: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9856914	A1	19981217
DESIGNATED STATES:	AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1998-US12098		19980612
PRIORITY (ORIGINAL):	US 1997-60/050063		19970613

L6 ANSWER 14 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent  
ACCESSION NUMBER: 1998043614 PCTFULL  
TITLE (ENGLISH): DRUG PREPARATIONS FOR TREATING SEXUAL DYSFUNCTION  
TITLE (FRENCH): PREPARATIONS MEDICAMENTEUSES POUR LE TRAITEMENT DE  
DYSFONCTIONS  
SEXUELLES  
INVENTOR(S): DRIZEN, Alan; ROTHBART, Peter; NATH, Gary, M.  
PATENT ASSIGNEE(S): LAM PHARMACEUTICALS, LLC  
LANGUAGE OF PUBL.: English  
LANGUAGE OF FILING: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9843614	A1	19981008
DESIGNATED STATES:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-US6020		19980327
PRIORITY (ORIGINAL):	US 1997-08/825121		19970328

L6 ANSWER 15 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent  
ACCESSION NUMBER: 1998031368 PCTFULL  
TITLE (ENGLISH): DOSAGE FORMS AND METHOD FOR AMELIORATING MALE  
ERECTILE  
DYSFUNCTION  
TITLE (FRENCH): FORMES ET PROCEDES PHARMACEUTIQUES DESTINES A  
AMELIORER LES  
DYSERECTIONS CHEZ L'HOMME  
INVENTOR(S): JOHNSON, Edward, Stewart; CLARKE, Anthony; GREEN,  
Richard, David  
PATENT ASSIGNEE(S): R.P. SCHERER LIMITED  
LANGUAGE OF PUBL.: English  
LANGUAGE OF FILING: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9831368	A1	19980723
DESIGNATED STATES:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-GB143		19980116
PRIORITY (ORIGINAL):	GB 1997-9700878.3		19970117

L6 ANSWER 16 OF 26 PCTFULL COPYRIGHT 2001 MicroPatent  
ACCESSION NUMBER: 1997029735 PCTFULL  
TITLE (ENGLISH): DERMAL PENETRATION ENHANCERS AND DRUG DELIVERY  
SYSTEMS  
INVOLVING

TITLE (FRENCH):	SAME PROMOTEURS DE PENETRATION DERMIQUE ET SYSTEME D'ADMINISTRATION DE MEDICAMENTS COMPRENANT CES PROMOTEURS
INVENTOR(S):	REED, Barry, Leonard; MORGAN, Timothy, Matthias; FINNIN, Barrie, Charles
PATENT ASSIGNEE(S):	MONASH UNIVERSITY; REED, Barry, Leonard; MORGAN, Timothy, Matthias; FINNIN, Barrie, Charles
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

  

	NUMBER	KIND	DATE
	-----	-----	-----
	WO 9729735	A1	19970821
DESIGNATED STATES:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SG SI SK TJ TM TR TT UA UG US UZ VN YU KE LS MW SD SZ UG AM AZ BY KG KZ TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1997-AU91		19970219
PRIORITY (ORIGINAL):	AU 1996-PN 8144		19960219

  

L6 ANSWER 17 OF 26	PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER:	1996040136 PCTFULL
TITLE (ENGLISH):	ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST
TITLE (FRENCH):	ANTAGONISTES DU RECEPTEUR 'alpha'-ADRENERGIQUE 1a
INVENTOR(S):	PATANE, Michael, A.; BOCK, Mark, G.; FREIDINGER, Roger, M.; PONTICELLO, Rose, Ann; NEWTON, Randall, C.
PATENT ASSIGNEE(S):	MERCK & CO., INC.; PATANE, Michael, A.; BOCK, Mark, G.; FREIDINGER, Roger, M.; PONTICELLO, Rose, Ann; NEWTON, Randall, C.
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

  

	NUMBER	KIND	DATE
	-----	-----	-----
	WO 9640136	A1	19961219
DESIGNATED STATES:	AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KG KR KZ LK LR LT LV MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN KE LS MW SD SZ AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1996-US9425		19960606
PRIORITY (ORIGINAL):	US 1995-8/488272		19950607

  

L6 ANSWER 18 OF 26	PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER:	1996040135 PCTFULL
TITLE (ENGLISH):	ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
TITLE (FRENCH):	ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
INVENTOR(S):	PATANE, Michael, A.; BOCK, Mark, G.; FREIDINGER, Roger, M.
PATENT ASSIGNEE(S):	MERCK & CO., INC.; PATANE, Michael, A.; BOCK, Mark, G.; FREIDINGER, Roger, M.
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

  

	NUMBER	KIND	DATE
--	--------	------	------

	WO 9640135	A1 19961219
DESIGNATED STATES:	AL AM AU AZ BB BG BR BY CA CN CZ EE GE HU IL IS JP KG KR KZ LK LR LT LV MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN KE LS MW SD SZ AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT BJ CF CG CI CM GA GN ML MR NE SN TD TG	
APPLICATION INFO.:	WO 1996-US9363	19960604
PRIORITY (ORIGINAL):	US 1995-8/488267	19950607

L6	ANSWER 19 OF 26	PCTFULL	COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER:		1996025934	PCTFULL
TITLE (ENGLISH):		ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS	
TITLE (FRENCH):		ANTAGONISTES DU RECEPTEUR ALPHA-1a-ADRENERGIQUE	
INVENTOR(S):		EVANS, Ben, E.; PONTICELLO, Gerald, S.; HOFFMAN, Jacob, M.; CHANG, Raymond, S., L.	
PATENT ASSIGNEE(S):		MERCK & CO., INC.; EVANS, Ben, E.; PONTICELLO, Gerald,	
		S.; HOFFMAN, Jacob, M.; CHANG, Raymond, S., L.	
LANGUAGE OF PUBL.:		English	
DOCUMENT TYPE:		Patent	
PATENT INFORMATION:			

	NUMBER	KIND	DATE
	-----		
	WO 9625934	A1	19960829
DESIGNATED STATES:	AL AM AU AZ BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KR KZ LK LR LT LV MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US US UZ VN KE LS MW SD AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1996-US2534		19960223
PRIORITY (ORIGINAL):	US 1995-8/392699		19950223
	US 1995-60/002534		19950818
	GB 1996-9603457.4		19960219

L6	ANSWER 20 OF 26	PCTFULL	COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER:		1996014897	PCTFULL
TITLE (ENGLISH):		DEVICE FOR THE TRANSDERMAL ADMINISTRATION OF MEDICAMENTS TO TREAT THE MALE ERECTILE IMPOTENCE	
TITLE (FRENCH):		DISPOSITIF D'ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS POUR LE TRAITEMENT DE L'IMPUISSANCE ERECTILE MASCULINE	
INVENTOR(S):		MILLOT, Philippe; LAMOISE, Michel	
PATENT ASSIGNEE(S):		LABORATOIRES D'HYGIENE ET DE DIETETIQUE (L.H.D.); MILLOT, Philippe; LAMOISE, Michel	
LANGUAGE OF PUBL.:		French	
DOCUMENT TYPE:		Patent	
PATENT INFORMATION:			

	NUMBER	KIND	DATE
	-----		
	WO 9614897	A1	19960523
DESIGNATED STATES:	AU CA CZ HU JP KR NZ PL SG SK US AT BE CH DE DK ES FR GB GR IE IT LU MC SE		
APPLICATION INFO.:	WO 1995-FR1510		19951116
PRIORITY (ORIGINAL):	FR 1994-94/13716		19941116

L6	ANSWER 21 OF 26	PCTFULL	COPYRIGHT 2001 MicroPatent
----	-----------------	---------	----------------------------

24  
ACCESSION NUMBER: 1992003141 PCTFULL  
TITLE (ENGLISH): TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF  
MALE  
IMPOTENCE  
TITLE (FRENCH): COMPOSITIONS TOPIQUES ET PROCEDES POUR LE TRAITEMENT  
DE  
L'IMPUISSANCE CHEZ L'HOMME  
INVENTOR(S): EL-RASHIDY, Ragab  
PATENT ASSIGNEE(S): PHARMEDIC CO.  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9203141	A1	19920305
DESIGNATED STATES:	AT BE CH DE DK ES FR GB GR IT JP LU NL SE		
APPLICATION INFO.:	WO 1991-US6028		19910826
PRIORITY (ORIGINAL):	US 1990-573518		19900827

✓  
① 103

L6 ANSWER 22 OF 26 USPATFULL  
ACCESSION NUMBER: 2000:88191 USPATFULL  
TITLE: Apomorphine and sildenafil composition  
INVENTOR(S): El-Rashidy, Ragab, Deerfield, IL, United States  
PATENT ASSIGNEE(S): Pentech Pharmaceuticals, Inc., Buffalo Grove, IL,  
United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6087362	20000711
APPLICATION INFO.:	US 1999-270035	19990316 (9)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Henley, III, Raymond	
LEGAL REPRESENTATIVE:	Olson & Hierl, Ltd.	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	899	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

✓  
② 103

L6 ANSWER 23 OF 26 USPATFULL  
ACCESSION NUMBER: 2000:31051 USPATFULL  
TITLE: Drug preparations for treating sexual dysfunction  
INVENTOR(S): Drizen, Alan, Ontario, Canada  
Rothbart, Peter, Ontario, Canada  
Nath, Gary M., Bethesda, MD, United States  
PATENT ASSIGNEE(S): L.A.M. Pharmaceutical Corp., Miami, FL, United States  
(U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6036977	20000314
APPLICATION INFO.:	US 1998-48335	19980326 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-825121, filed on 28 Mar 1997, now patented, Pat. No. US 5952006	

which

is a continuation-in-part of Ser. No. US 1997-796578,  
filed on 6 Feb 1997, now patented, Pat. No. US 5897880  
which is a continuation-in-part of Ser. No. US  
1995-536750, filed on 29 Sep 1995, now abandoned

DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Harrison, Robert H.  
LEGAL REPRESENTATIVE: Nath, Gary M.; Yarnell, Scott F. Nath & Associates  
NUMBER OF CLAIMS: 39  
EXEMPLARY CLAIM: 1  
LINE COUNT: 934  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 26 USPATFULL  
ACCESSION NUMBER: 1999:53087 USPATFULL  
TITLE: Device for percutaneous administration of medicaments  
for treating male impotence  
INVENTOR(S): Millot, Philippe, Dijon, France  
Lamoise, Michel, Bessey-les-Citeaux, France  
PATENT ASSIGNEE(S): Laboratoires D'Hygiene et de Dietetique (L.H.D.),  
Paris, France (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5899875	19990504
	WO 9614897	19960523
APPLICATION INFO.:	US 1997-836350	19970512 (8)
	WO 1995-FR1510	19951116
		19970512 PCT 371 date
		19970512 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1994-13716	19941116
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Coggins, Wynn Wood	
ASSISTANT EXAMINER:	Finkel, Sharon	
LEGAL REPRESENTATIVE:	Stevens, Davis, Miller & Mosher, L.L.P.	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	379	

L6 ANSWER 25 OF 26 USPATFULL  
ACCESSION NUMBER: 1999:893 USPATFULL  
TITLE: Venous flow control element for maintaining penile  
erection  
INVENTOR(S): Place, Virgil A., Kawaihae, HI, United States  
PATENT ASSIGNEE(S): Vivus, Incorporated, Mountain View, CA, United States  
(U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5855548	19990105
APPLICATION INFO.:	US 1997-782867	19970110 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-664423, filed on 14 Jun 1996, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Bahr, Jennifer	
ASSISTANT EXAMINER:	Kearney, Rosiland	
LEGAL REPRESENTATIVE:	Reed, Dianne E. Bozicevic & Reed LLP	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)  
LINE COUNT: 956

L6 ANSWER 26 OF 26 USPATFULL

ACCESSION NUMBER: 1998:30702 USPATFULL

TITLE: Medication for impotence containing lyophilized roe  
and

INVENTOR(S): a powdered extract of Ginkgo biloba  
Omar, Lotfy Ismail, P.O. Box F396, Kew Gardens, NY,  
United States 11415

	NUMBER	DATE
PATENT INFORMATION:	US 5730987	19980324
APPLICATION INFO.:	US 1996-660875	19960610 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Naff, David M.	
ASSISTANT EXAMINER:	Kerr, Janet M.	
LEGAL REPRESENTATIVE:	Kroll, Michael I.	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	478	

CLM In this invention, a peripheral vasodilator which enhances the maintenance of penis **erection** by a male is combined with a pharmacologically acceptable enhancer to facilitate absorption of the vasodilator through the skin and a pharmacologically acceptable topical. . . 2-methylcyclodextrin. This most preferred cyclodextrin for the composition herein is hydroxypropyl- $\beta$ -cyclodextrin (HPBCD herein). This invention is particularly useful to diabetic men who have become **impotent** as a result of their diabetes.

An alpha receptor blocker may be combined with the peripheral vasodilator, if desired. A preferred alpha receptor blocker is **phentolamine** which is represented by the formula:

other suitable alpha receptor blockers are phenoxybenzamine, **yohimbine**, prazosin, tolazoline and the like. These blockers are usually present in a concentration of about 0.05 to about 0.5 percent by weight of. . . range of about 20:1 to about 200:1, preferably about 30:1 to about 50:1. Optionally, the present compositions can also include androgens such as **testosterone** and the like.

Maintenance of penis **erection** may be further enhanced by restricting blood flow from the penis after the **erection** is enhanced by the peripheral vasodilator.

of the vasoconstrictor should be time delayed to act upon the penis after the peripheral vasodilator has enhanced the maintenance of the penis **erection**. This time delay may be accomplished by utilizing water-insoluble, lipophilic norepinephrine salts (such as benzoate) which will slowly be absorbed through the skin. . .

9 1

#### TABLE I

#### REPRESENTATIVE TOPICAL PAPAVERINE GELS

C

#### Gel Preparation

Ingredients, wt%

Papaverine HCl 1 3.0 3.0 3.0 3.0 3.0 3.0 3.0

#### **Phentolamine**

mycelate 2 0.1 0.1 0.1 0.1 0.1 0.1

Norepinephrine 3 0.001 0.001 0.001 0.001 0.001 0.001 0

Ethanol 35.0 30.0 30.0 35.0. . .

To enhance an **erection**, a sufficient amount of the present composition is applied directly to the penis prior to coitus. The topical composition containing papaverine and HPBCD. . .

An effective amount or dosage needed to enhance an **erection** usually is about 50 to about 500

milligrams of the peripheral vasodilator per application. Preferably, about 75 to about 150 milligrams of the. . .

of trials have been conducted under physician supervision in volunteers diagnosed with premature ejaculation and who have not been able to maintain an **erection** for coitus. These patients were young, healthy subjects with normal vascular integrity and were undergoing treatment with intracavernosal injections of 30 mg doses. . . 11; 50 mg dose of papaverine). The patients were asked for a subjective evaluation of efficacy based on the quality of their **erection** (rigidity) and the duration of action. The patients were instructed to apply the topical preparation in the following manner;  
1. Empty entire contents. . .

tumescence and duration. There were no reports of irritation. In those patients that experienced a positive response to treatment, the duration of their **erections** were approximately 10-15 minutes as compared to one hour with injection, and 2 minutes or less with no drug treatments.

#### CLAIMS ..CLM:

##### I CLAIMS

1. An aqueous topical composition suitable for enhancing the maintenance of penis **erection** by a male patient which comprises a peripheral vasodilator and hy4roxypropyl-p-cyclodextrin present in a molar ratio in the range of about 1 to. . . 1.4, respectively, and in a pharmacologically acceptable topical vehicle for said vasodilator; said peripheral vasodilator being present in an amount sufficient to enhance penis **erection**.

9. The composition in accordance with claim 4 wherein said alpha receptor blocker is **phentolamine**.

16. A method for enhancing the maintenance of penis **erection** by a male patient which comprises the topical application to the penis of an effective, **erection** enhancing, amount of a composition comprising a peripheral vasodilator and a hydroxypropyl-p-cyclodextrin in a pharmacologically acceptable topical vehicle for said vasodilator and. . .

18. The method in accordance with claim 16 wherein the peripheral vasodilator is papaverine and wherein the composition additionally includes 6 **phentolamine**.

19. The method in accordance with claim 16 further comprising a means for restricting blood flow from the penis after the penis **erection** is enhanced.

L6 ANSWER 22 OF 26 USPATFULL

CLM What is claimed is:

1. A method suitable for treating **erectile dysfunction** in a human patient which comprises administering to said patient prior to **sexual** activity **apomorphine** or a pharmaceutically acceptable acid addition salt thereof and **sildenafil** or a pharmaceutically acceptable acid addition salt thereof each being administered in an amount sufficient to induce and maintain an **erection** adequate for sustaining satisfaction during **sexual** activity but less than an amount that induces substantial nausea.

2. The method in accordance with claim 1 wherein the **apomorphine** and **sildenafil** are co-administered in a single dosage unit comprising about 1 to about 6 mg **apomorphine** and about 10 to about 75 mg **sildenafil**.

3. The method in accordance with claim 2 wherein the single dosage unit comprises about 2 to about 5 mg **apomorphine** and about 15 to about 50 mg **sildenafil**.

4. The method in accordance with claim 1 wherein the **sildenafil** and **apomorphine** is sequentially administered by first administering a dosage unit comprising **sildenafil** in an amount in the range of about 10 to about 75 mg and then a dosage unit comprising **apomorphine** in an amount in the range of about 1 to about 6 mg.

5. The method in accordance with claim 4 wherein the amount of administered **apomorphine** is in a range of about 2 to 5 mg.

6. The method in accordance with claim 4 wherein the amount of administered **sildenafil** is in a range of about 15 to about 50 mg.

7. The method in accordance with claim 4 wherein the amount of administered **apomorphine** is in a range of about 2 to about 5 mg and the amount of administered **sildenafil** is in a range of about 15 to about 50 mg.

8. The method in accordance with claim 4 wherein the **sildenafil** is administered within about 30-60 minutes of **apomorphine** administration.

10. A pharmaceutical composition comprising **sildenafil** and **apomorphine** in a pharmaceutically acceptable vehicle.

11. The composition of claim 10 wherein the amount of **sildenafil** is in the range of about 10 to about 25 mg.

12. The composition of claim 10 wherein the amount of **apomorphine** is in the range of about 1 to about 6 mg.

14. A pharmaceutical composition comprising **sildenafil** and a cyclodextrin in a pharmaceutically acceptable vehicle.

16. The composition of claim 15 wherein the amount of **sildenafil** is about 20 mg and the amount of hydroxypropyl-beta-cyclodextrin is

about 1 to about 10% by weight of the total. . .

17. The composition of claim 10 further including **erectogenic** agents selected from adrenal steroids, alpha receptor blockers, or peripheral vasodilators added at a concentration in the range of about 50 to about 100 percent by weight of the weight of **apomorphine**

.

18. The composition of claim 17 wherein the **erectogenic** agent is an adrenal steroid selected from the group consisting of **testosterone** and dehydroepiandrosterone.

19. The composition of claim 17 wherein the **erectogenic** agent is an alpha receptor blocker selected from the group consisting of **phentolamine, yohimbine**, prazosin, doxazosin, terazosin, and trimazosin.

20. The composition of claim 17 wherein the **erectogenic** agent is prostaglandin E.sub.1.

L6 . . . MicroPatent

15

CLM CLAIMS

The use of a pharmaceutical composition for oral administration comprising a carrier and active ingredient selected from a dopamine agonist, **testosterone** and mixtures thereof, the composition being in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity for the manufacture of a medicament for treatment of male **erectile dysfunction**.

claims in which the dopamine agonist is **apomorphine** or a salt thereof.

10. The use as claimed in any preceding claim in which the active ingredient comprises **testosterone**.

ii. The use as claimed in claim 10 in which the is **testosterone** is present in an amount of 10 to 100mg.

12. A method of treating male **erectile dysfunction** which comprises administering to the oral cavity of a patient a dopamine agonist and/or **testosterone** in a fast-dispersing dosage form designed to release active ingredients rapidly in the oral cavity.

L6 . . . 23. A drug delivery system according to any one of claims 11 to 22, characterised in that the physiologically active agent is **testosterone**, oestradiol, ethinyloestradiol, progesterone, norethisterone acetate, ibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, fentanyl, buprenorphine, scopolamine, prochlorperazine, metochlopramide, ondansetron, tamoxifen, epitioestanol, exemestane, 4-hydroxy-androstenedione and its derivatives, finasteride, turosteride, LY191704, MK-306, alprazolam, **alprostadil**, prostacyclin and its derivatives, melatonin, ri-docosanol, tromantadine, lipophilic pro-drugs of acyclovir, low molecular weight heparin, enoxaparin, sumatriptan, amlodipine, nitrendipine, primaquine, minoxidil, minoxidil pro-drugs, pilocarpine, salbutamol, terbutaline, salmeterol, . . .

16

29. A method according to claim 28, characterised in that the disease or condition requires male hormone replacement in **testosterone** deficient hypogonadal men, female hormone replacement therapy for postmenopausal women, androgen replacement therapy for females lacking libido, male contraception or female contraception.

soft

tissue injury, narcotic withdrawal, severe post-operative pain, motion sickness, oestrogen dependent breast cancer, prostatic enlargement and/or prostatic cancer, alopecia and acne, anxiety disorders, male **impotence**, Raynauds syndrome and varicose veins, sleep disorders, jetlag, herpes virus infections, deep vein thrombosis, migraine, high blood pressure, malaria, diagnosis of cystic fibrosis, asthma. . .

CLM 1. A method for the treatment of **sexual dysfunction** in an animal, which comprises:

topically applying to a specific site on the surface of an animal a therapeutically effective amount of a drug for treating **sexual dysfunction** dispersed within a gelled composition comprising a polymer matrix which is suspended in a liquid medium, wherein the polymer matrix contains a negative. . .

6. The method of claim 1, wherein the drug for treating **sexual dysfunction** is effective in treating **impotency** in a male.

7. The method of claim 1, wherein the drug for treating **sexual dysfunction** is effective in treating vaginal dryness in a female.

12. The method of claim 1, wherein the drug for treating **sexual dysfunction** is selected from the group consisting of papaverine, **phentolamine**, prostaglandin E<sub>1</sub>, nicotinic acid, glycerol, propylene glycol, **testosterone**, **testosterone** propionate, glucocorticoids, hydrocortisone, gamma-linolenic acid (GLA), dihomogamma-linolenic acid (DGLA) and mixtures thereof.

method of claim 1, wherein the therapeutically effective amount of the drug penetrates the exterior layers of the penis causing an **erection** without significantly modifying motor or sensory functions.

15. A method for the treatment of **erectile dysfunction** in a male animal, which comprises:

topically applying to the surface of a penis a therapeutically effective amount of a drug for treating **impotency** dispersed within a gelled composition comprising a polymer matrix which is suspended in a liquid medium; wherein the polymer matrix contains a. . .

24. The method of claim 15, wherein the drug for treating **impotency** is selected from the group consisting of papaverine, **phentolamine**, prostaglandin E<sub>1</sub>, and mixtures thereof.

25. The method of claim 15, wherein the therapeutically effective dose penetrates the exterior layers of the penis causing an **erection** without significantly modifying motor or sensory functions. .

26. A gelled composition for treating **impotency**, which comprises: therapeutically effective amounts of a drug for treating **impotency** dispersed within a matrix containing a negative charged polymer blended with a nonionic polymer, wherein the molar ratio of the negative

charged polymer. . .

31. A method for the treatment of **erectile dysfunction** in male animals, which comprises:

39. The method of claim 31, wherein the drug dispersed in the gelled composition is selected from the group consisting of papaverine, **phentolamine**, prostaglandin E1. and mixtures thereof.

40. The method of claim 31, wherein the therapeutically effective dose penetrates the exterior layers of the penis causing an **erection** without significantly modifying motor or sensory functions.

41. A method for the treatment of **sexual dysfunction** resulting from vaginal dryness in a female animal, which comprises:

topically applying to a vagina a therapeutically effective amount of a drug for treating female **sexual dysfunction** caused by vaginal dryness dispersed within a gelled composition comprising a polymer matrix which is suspended in a liquid medium; wherein the. . .

46. The method of claim 41, wherein the drug for treating **sexual dysfunction** caused by vaginal dryness is selected from the group consisting of prostaglandin E,, nicotinic acid, glycerol, propylene glycol, **testosterone**, **testosterone** propionate, glucocorticoids, hydrocortisone, gamma-linolenic acid (GLA), dihomogamma-linolenic acid (DGLA), Yerba Santa extract and mixtures thereof.

47. A gelled composition for treating **sexual dysfunction** resulting in vaginal dryness, which comprises:

is therapeutically effective amounts of a drug for treating **sexual dysfunction** caused by vaginal dryness dispersed within a matrix containing a negative charged polymer having a mean average molecular weight between about 650,000 and. . .

49. The gelled composition of claim 47, wherein the drug for treating **sexual dysfunction** caused by vaginal dryness is selected from the group consisting of prostaglandin E,, nicotinic acid, glycerol, propylene glycol, **testosterone**, **testosterone** propionate, glucocorticoids, hydrocortisone, gamma-linolenic acid (GLA), dihomogamma-linolenic acid (DGLA), Yerba Santa extract and mixtures thereof.

14

=> d ibib 1-5

L9 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2001 MicroPatent  
ACCESSION NUMBER: 1998043614 PCTFULL  
TITLE (ENGLISH): DRUG PREPARATIONS FOR TREATING SEXUAL DYSFUNCTION  
TITLE (FRENCH): PREPARATIONS MEDICAMENTEUSES POUR LE TRAITEMENT DE  
DYSFONCTIONS  
SEXUELLES  
INVENTOR(S): DRIZEN, Alan; ROTHBART, Peter; NATH, Gary, M.  
PATENT ASSIGNEE(S): LAM PHARMACEUTICALS, LLC  
LANGUAGE OF PUBL.: English  
LANGUAGE OF FILING: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9843614	A1	19981008
DESIGNATED STATES:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-US6020		19980327
PRIORITY (ORIGINAL):	US 1997-08/825121		19970328

L9 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2001 MicroPatent  
ACCESSION NUMBER: 1998031368 PCTFULL  
TITLE (ENGLISH): DOSAGE FORMS AND METHOD FOR AMELIORATING MALE  
ERECTILE  
DYSFUNCTION  
TITLE (FRENCH): FORMES ET PROCEDES PHARMACEUTIQUES DESTINES A  
AMELIORER LES  
DYSERECTIONS CHEZ L'HOMME  
INVENTOR(S): JOHNSON, Edward, Stewart; CLARKE, Anthony; GREEN,  
Richard, David  
PATENT ASSIGNEE(S): R.P. SCHERER LIMITED  
LANGUAGE OF PUBL.: English  
LANGUAGE OF FILING: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9831368	A1	19980723
DESIGNATED STATES:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-GB143		19980116
PRIORITY (ORIGINAL):	GB 1997-9700878.3		19970117

L9 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2001 MicroPatent  
ACCESSION NUMBER: 1993015104 PCTFULL  
TITLE (ENGLISH): 20-SUBSTITUTED PREGNENE DERIVATIVES AND THEIR USE AS

ANDROGEN  
 SYNTHESIS INHIBITORS  
 TITLE (FRENCH): DERIVES DE PREGNENE SUBSTITUES EN POSITION 20 ET LEUR  
 UTILISATION  
 EN TANT QU'INHIBITEURS DE LA SYNTHSE D'ANDROGENES  
 INVENTOR(S): BRODIE, Angela; LI, Jisong  
 PATENT ASSIGNEE(S): RESEARCH CORPORATION TECHNOLOGIES, INC.  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9315104	A1	19930805
DESIGNATED STATES:	AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT		
	SE		
APPLICATION INFO.:	WO 1993-US760		19930128
PRIORITY (ORIGINAL):	US 1992-7/827040		19920129

L9 ANSWER 4 OF 5 USPATFULL

ACCESSION NUMBER: 2000:31051 USPATFULL  
 TITLE: Drug preparations for treating sexual dysfunction  
 INVENTOR(S): Drizen, Alan, Ontario, Canada  
 Rothbart, Peter, Ontario, Canada  
 Nath, Gary M., Bethesda, MD, United States  
 PATENT ASSIGNEE(S): L.A.M. Pharmaceutical Corp., Miami, FL, United States  
 (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6036977	20000314
APPLICATION INFO.:	US 1998-48335	19980326 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-825121, filed on 28 Mar 1997, now patented, Pat. No. US 5952006	

which

is a continuation-in-part of Ser. No. US 1997-796578,  
 filed on 6 Feb 1997, now patented, Pat. No. US 5897880  
 which is a continuation-in-part of Ser. No. US  
 1995-536750, filed on 29 Sep 1995, now abandoned

DOCUMENT TYPE: Utility  
 PRIMARY EXAMINER: Harrison, Robert H.  
 LEGAL REPRESENTATIVE: Nath, Gary M.; Yarnell, Scott F. Nath & Associates  
 NUMBER OF CLAIMS: 39  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 934  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 5 USPATFULL

ACCESSION NUMBER: 1998:30702 USPATFULL  
 TITLE: Medication for impotence containing lyophilized roe  
 and  
 a powdered extract of Ginkgo biloba  
 INVENTOR(S): Omar, Lotfy Ismail, P.O. Box F396, Kew Gardens, NY,  
 United States 11415

	NUMBER	DATE
PATENT INFORMATION:	US 5730987	19980324
APPLICATION INFO.:	US 1996-660875	19960610 (8)

DOCUMENT TYPE: Utility  
PRIMARY EXAMINER: Naff, David M.  
ASSISTANT EXAMINER: Kerr, Janet M.  
LEGAL REPRESENTATIVE: Kroll, Michael I.  
NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)  
LINE COUNT: 478

=> d kwic 1-5

L9 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2001 MicroPatent

CLM 46. The method of claim 41, wherein the drug for treating **sexual dysfunction** caused by vaginal dryness is selected from the group consisting of prostaglandin E,, nicotinic acid, glycerol, propylene glycol, **testosterone**, **testosterone** propionate, glucocorticoids, hydrocortisone, gamma-linolenic acid (GLA), dihomogamma-linolenic acid (DGLA), Yerba Santa extract and mixtures thereof.

49. The gelled composition of claim 47, wherein the drug for treating **sexual dysfunction** caused by vaginal dryness is selected from the group consisting of prostaglandin E,, nicotinic acid, glycerol, propylene glycol, **testosterone**, **testosterone** propionate, glucocorticoids, hydrocortisone, gamma-linolenic acid (GLA), dihomogamma-linolenic acid (DGLA), Yerba Santa extract and mixtures thereof.

L9 . . . MicroPatent

CLM CLAIMS  
The use of a pharmaceutical composition for oral administration comprising a carrier and active ingredient selected from a dopamine agonist, **testosterone** and mixtures thereof, the composition being in the form of a fast-dispersing dosage form designed to release the active ingredient rapidly in the oral cavity for the manufacture of a medicament for treatment of male **erectile dysfunction**.

12. A method of treating male **erectile dysfunction** which comprises administering to the oral cavity of a patient a dopamine agonist and/or **testosterone** in a fast-dispersing dosage form designed to release active ingredients rapidly in the oral cavity.

L9 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2001 MicroPatent

CLM The 5(alpha)-reductase inhibitors, 4-MA and finasteride, were noted to increase **testosterone** levels [18]. Although this effect may be beneficial in treating men with BPH without causing gynecomastia and **impotence**, inhibition of all androgen production is an important goal

of treatment for prostatic cancer. The 20-substituted-pregnene derivatives, of which 4-pregnen-3-one-20(beta)-aldoxime is an . . . example, may be of value in this treatment because of their dual action in reducing androgen production by inhibiting synthesis of the substrate (**testosterone**) and the activity of the 5(alpha)-reductase.

L9 ANSWER 4 OF 5 USPATFULL

CLM What is claimed is:

36. The method of claim 33, wherein the drug for treating **sexual dysfunction** caused by vaginal dryness is selected from the group consisting of prostaglandin E.sub.1, nicotinic acid, glycerol, propylene glycol, **testosterone**, **testosterone** propionate, glucocorticoids, hydrocortisone, gamma-linolenic acid (GLA), dihomogamma-linolenic acid (DGLA), Yerba Santa extract and mixtures thereof.

39. The gelled composition of claim 37, wherein the drug for treating **sexual dysfunction** caused by vaginal dryness is selected from the group consisting of prostaglandin E.sub.1, nicotinic acid, glycerol, propylene glycol, **testosterone**, **testosterone** propionate, glucocorticoids, hydrocortisone, gamma-linolenic acid (GLA), dihomogamma-linolenic acid (DGLA), Yerba Santa extract and mixtures thereof.

L9 ANSWER 5 OF 5 USPATFULL

CLM What is claimed is:

8. The composition for treating **impotence** in human males according to claim 6, wherein said hormone is **testosterone** or a derivative thereof.